Why the study?
Does Left Ventricular Augmentation with Algisyl in addition to SMT improve exercise capacity, symptoms, and clinical status in patients with advanced HF?
Does Left Ventricular Augmentation with Algisyl in addition to SMT improve exercise capacity, symptoms, and clinical status in patients with advanced HF?
Left ventricular augmentation with Algisyl added to standard medical therapy provides sustained 1-year improvements in exercise capacity and symptoms in patients with advanced heart failure.
Answers are grounded in this paper and cite their sources.
Opens a new treatment axis for advanced HF; extends evidence for LV augmentation to sustained 1-year outcomes.
Algisyl in addition to SMT was more effective than SMT alone for providing sustained 1-year benefits in exercise capacity, symptoms, and clinical status for patients with advanced HF. These data support larger clinical evaluations of this novel therapy.
No takes yet. Share an insight, caveat, or question.
Mann et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: